TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01047488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine, pregabalin
Description: Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
Study: NCT01039740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine administration for 6 weeks under therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine administration for 6 weeks under therapeutic dose
Study: NCT06096467

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehension Exercise Training
Description: Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehension Exercise Training
Description: Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo milk
Description: Placebo milk: 8 g. protein for each serving and provided immediately after the CET session

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Description: Protein Supplement: 40 g. whey protein for each serving and provided immediately after the CET session
Study: NCT00494676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High power (57 prism diopter) peripheral prism glasses
Description: All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High power (57 prism diopter) peripheral prism glasses
Description: All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low power sham peripheral prism glasses
Description: Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low power sham peripheral prism glasses
Description: Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
Study: NCT01110616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam
Study: NCT04311736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergame
Description: Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: Cycling on a recumbent cycle ergometer

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching
Description: Stretching exercises
Study: NCT03055754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon randomized arm
Description: Endoscopic argon plasma coagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: No Endoscopic procedure
Study: NCT03333642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal Ileal Interposition with Sleeve Gastrectomy
Description: Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
Study: NCT03151720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
Study: NCT03754140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Injection
Description: Sclerotic agent
Study: NCT01129362

Intervention type: BIOLOGICAL
Intervention: Pentacel® (DTaP-IPV/Hib)
Description: 0.5 mL dose, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Other Pertussis Vaccines
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Other Pertussis Vaccines
Description: 0.5 mL, Intramuscular
Study: NCT01776762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individual nutritional therapy
Description: Individual nutritional therapy provided by registered dietician by means of three Home-visits
Study: NCT02716675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by IV infusion; total dose will vary based on participant's weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by IV infusion; total dose will vary based on participant's weight

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VRC01
Description: Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
Study: NCT04906356

Intervention type: GENETIC
Intervention: Genetic sub-study
Description: One time saliva sample collection
Study: NCT04256460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy diet, regular exercises and peer support
Description: After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
Study: NCT02809131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polymixin/bacitracin
Description: Antibacterial irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalexin, or levofloxacin, or clindamycin
Description: Post operative oral antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline irrigation
Study: NCT04067479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: Oral bolus of essential amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: Oral bolus of essential amino acids
Study: NCT04022187

Intervention type: OTHER
Intervention: Observational study : no intervention
Description: Observational study : no intervention, only exporting data
Study: NCT04559191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous glucose monitoring (CGM)
Description: CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
Study: NCT04092296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin infiltration
Description: using infiltrant resin intervene proximal caries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: remineralization
Description: using fluoride to remineralize proximal caries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham
Description: replace resin with water
Study: NCT02705521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergames- Laptop and MIcrosoft Kinect
Description: Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
Study: NCT03974087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 2mA stimulation for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 2mA stimulation for 20 minutes
Study: NCT01411020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
Study: NCT03685383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb removal column in eCPR
Description: In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard eCPR (va-ECMO)
Description: Standard treatment in eCPR with a established va-ECMO system.
Study: NCT03936621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 fatty acid
Description: To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
Study: NCT01172197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Femoral bolus 150μM followed by femoral infusion 400μM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Bolus and infusion
Study: NCT01111942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radiation combined with weekly carboplatin
Description: recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta\* 6 mg SC Day 5 (\*Neupogen may be substituted at the investigator's discretion)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conservation surgery
Description: Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
Study: NCT00187096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
Description: See Detailed Description section for additional details of treatment interventions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2
Description: See Detailed Description section for additional details of treatment interventions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Infusion
Description: See Detailed Description section for additional details of treatment interventions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Infusion
Description: See Detailed Description section for additional details of treatment interventions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS System
Description: See Detailed Description section for additional details of treatment interventions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS System
Description: See Detailed Description section for additional details of treatment interventions.
Study: NCT03883191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder
Description: Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking 1 pack of placebo powder three times a day before meals for three months.
Study: NCT00861250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib + dexamethasone
Description: Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
Study: NCT01150175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endomyocardial Injection of Autologous Bone Marrow Cells
Description: Endomyocardial Injection of Autologous Bone Marrow Cells

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endomyocardial Injection of Plasma
Description: Endomyocardial Injection of Plasma
Study: NCT00533143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive ventilation (NIV)
Description: NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
Study: NCT03175354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
Description: Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-101 Gel 5% and ALX-101 Gel Vehicle
Description: Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
Study: NCT03804736

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT-c
Description: Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT-c Lactobacillus
Description: Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
Study: NCT04511832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.